Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.

Détails

ID Serval
serval:BIB_CDCE3AC07754
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Périodique
European journal of cancer
Auteur(s)
Dimitriou F., Zaremba A., Allayous C., Kähler K.C., Gerard C.L., Festino L., Schäfer S., Toussaint F., Heinzerling L., Hassel J.C., Ascierto P.A., Michielin O., Hauschild A., Lebbe C., Livingstone E., Ramelyte E., Cheng P.F., Dummer R., Mangana J.
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Statut éditorial
Publié
Date de publication
05/2021
Peer-reviewed
Oui
Volume
149
Pages
37-48
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Anti-PD1-based immunotherapy is currently used in most patients with advanced melanoma. Despite the remarkable data regarding overall survival, the optimal treatment duration is still unknown.
We evaluated the outcome of 125 patients with advanced melanoma with and without brain metastases (MBM), treated either with anti-PD1 monotherapy (N = 97) or combined with anti-CTLA4 (N = 28) after elective treatment discontinuation due to complete response (CR) (group A, N = 86), or treatment-limiting toxicity (N = 33) and investigator's decision (ID, N = 6) (group B) with subsequent CR.
For group A, median duration of treatment (mDoT) was 22 months (range 5-49) and median time to CR 9 months (range 2-47). Accordingly, mDoT for group B was 3 months (range 0-36) and median time to CR 7 months (range 1-32). Seven patients from group A and three from group B experienced disease recurrence. Off-treatment survival was not reached. Median off-treatment response time (mOTRt) was 19 months (range 0-42) and 25 months (range 0-66), respectively. For MBM, mOTRt was 17 months (range 7-41) and 28 months (range 9-39), respectively. After a median follow-up of 38 months (range 9-70), seven (5.6%) patients had deceased, one (0.8%) due to melanoma.
Treatment discontinuation is feasible also in patients with MBM. Efficacy outcomes seemed to be similar in both groups of patients who achieved CR, regardless of reason for discontinuation. In patients who experienced disease relapse, treatment re-challenge with anti-PD1 resulted in subsequent renewed response.
Mots-clé
Anti-PD1 treatment, Brain metastases, Discontinuation, Immunotherapy, Melanoma
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/04/2021 12:13
Dernière modification de la notice
12/10/2021 6:39
Données d'usage